Clinical Trial

Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac Amyloidosis

Study acronym: PeakAmyL
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 26, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Transthyretin cardiac amyloidosis (ATTR-CA) is traditionally diagnosed using planar bone scintigraphy with a Perugini visual score ≥ 2. Fast cardiac CZT-SPECT will be evaluated for its ability to reproduce this classification and provide reproducible quantitative myocardial uptake metrics.
Trial Details
NCT Number NCT07605741
Lead Sponsor Central Hospital, Nancy, France
Conditions Cardiac Amyloidosis
Enrollment 200 participants
Start Date 2026-05-30
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-26